ReviewDermatologie (Heidelberg, Germany)2025
[Primary cutaneous B-cell lymphomas-an overview of established and novel aspects].
Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous B‑cell lymphomas (PCBCL) belong to the group of extranodal non-Hodgkin lymphomas and by definition only manifest on the skin at the time of diagnosis. These lymphomas can be broadly classified into indolent and aggressive subtypes. Indolent PCBCLs include primary cutaneous marginal zone lymphoma, primary cutaneous follicular B‑cell lymphoma and Epstein-Barr virus-positive mucocutaneous ulcer, which present solitary or multifocal lesions and are associated with a favorable prognosis. Treatment usually involves excision or radiotherapy, although a watch-and-wait concept can also be discussed. Conversely, aggressive PCBCLs, such as primary cutaneous diffuse large B‑cell lymphoma, leg type, and primary cutaneous intravascular large B‑cell lymphoma, carry a high risk of systemic dissemination. Consequently, they require systemic treatment. The standard first-line therapy is typically the R‑CHOP regimen, which may be supplemented with radiotherapy.
Indexed as
Identifiers
41128869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.